Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
17.28
+0.30 (1.77%)
At close: Aug 7, 2025, 4:00 PM
17.28
0.00 (0.00%)
After-hours: Aug 7, 2025, 5:52 PM EDT

Company Description

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).

It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial.

The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.

Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Sionna Therapeutics, Inc.
Sionna Therapeutics logo
CountryUnited States
Founded2019
IPO DateFeb 7, 2025
IndustryBiotechnology
SectorHealthcare
Employees41
CEOMichael Cloonan

Contact Details

Address:
21 Hickory Drive, Suite 500
Waltham, Massachusetts 02451
United States
Phone617 819 2020
Websitesionnatx.com

Stock Details

Ticker SymbolSION
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code0002036042
CUSIP Number829401108
ISIN NumberUS8294011080
SIC Code2834

Key Executives

NamePosition
Michael Cloonan M.B.A.President, Chief Executive Officer and Director
Elena H. Ridloff C.F.A.Chief Financial Officer and Head of Corporate Development
Dr. Charlotte McKee M.D.Chief Medical Officer
Dr. Greg Hurlbut Ph.D.Co-Founder and Senior Vice President of Discovery Research
Dr. Mark Munson Ph.D.Co-founder and Senior Vice President of Medicinal Chemistry
Meghan BagshawVice President of Programs, Portfolio and Operations
Andy ChuVice President of Information and Technology
Jennifer Fitzpatrick J.D.Chief Legal Officer
Vanya SagarChief People Officer
Mara Furlow M.S.Senior Vice President of Global Regulatory Affairs and Quality

Latest SEC Filings

DateTypeTitle
Jul 30, 2025SCHEDULE 13GFiling
Jun 16, 2025SCHEDULE 13GFiling
Jun 13, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
Apr 29, 2025ARSFiling
Apr 29, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025DEF 14AOther definitive proxy statements
Mar 20, 202510-KAnnual Report